Neurotrope Inc (NTRP) 0.5800 $NTRP Neurotrope to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Neurotrope Inc (NTRP) 0.5800 $NTRP

Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer's Disease at the 2015 Alzheimer's Association International Conference
PR Newswire - Mon Jul 20, 10:08AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the "Company" will be showcasing bryostatin as a potential treatment for Alzheimer's Disease at the Alzheimer's Association International Conference(R) (AAIC) being held July 18-23, 2015, in Washington, DC.

Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease
PR Newswire - Wed Jun 24, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its operating wholly-owned subsidiary ("Neurotrope", will conduct a preclinical study, in collaboration with a leading research institution, to examine the effect of bryostatin in Niemann-Pick type C (NPC) mice. The study is being funded by several family foundations under the auspices of Support Of Accelerated Research for NPC Disease ("SOAR-NPC".

Neurotrope to Present Findings of In-vitro Studies of Bryostatin's Effects on Niemann Pick Type C1 Cells at the Annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C
PR Newswire - Fri Jun 12, 7:30AM CDT
Neurotrope Bioscience, Inc. (Neurotrope or the Company), the operating subsidiary of Neurotrope, Inc. (OTCQB: NTRP) today announced the Company will present the findings of in vitro studies of bryostatin's effects on Niemann Pick Type C1 cells (NPC1 cells) at the annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C research to be held on June 11 -13, 2015 at the University of Notre Dame. The Company's presentation will take place on Friday, June 12, at 2:30 pm Eastern time.

Neurotrope Tackling Alzheimer's, Other Orphan Indications
Jason Napodano, CFA - at Seeking Alpha - Mon May 18, 4:21PM CDT


Neurotrope Joins National Organization for Rare Disorders (NORD) Corporate Council
PR Newswire - Thu Apr 23, 7:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that, based upon its work in orphan drug indications, it has been invited to join the National Organization for Rare Disorders (NORD) as a member of the NORD Corporate Council. NORD is a leading independent, non-profit organization committed to the identification, treatment, and cure of rare disorders.

Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research
PR Newswire - Mon Apr 20, 7:35AM CDT
In the search for neuroscience drug discovery treatments, Alzheimer's disease and specifically autism drug candidates, a few viable therapeutic approaches have come from research on neurological conditions such as fragile X syndrome. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), CytRx Corporation (NASDAQ: CYTR), Trovagene, Inc., (NASDAQ: TROV), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Abbot Laboratories (NYSE: ABT) & Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX).
ABT: 41.89 (+0.73), LXRX: 11.59 (-0.05), TROV: 5.72 (+0.11), CYTR: 2.82 (-0.02), BMY: 61.44 (+0.93), ARNA: 2.19 (+0.14)

Neurotrope Receives Research Grant From the FRAXA Research Foundation to Fund Pre-Clinical Fragile X Syndrome Behavioral Studies
PR Newswire - Mon Apr 20, 6:55AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that eurotrope BioScience, Inc., its wholly-owned operating subsidiary, has received a grant from the FRAXA Research Foundation, Inc. ("FRAXA" to fund a pre-clinical Fragile X Syndrome ("FXS" behavior study for its lead proprietary drug candidate, bryostatin, at FRAXA's purpose built laboratory located at the University of Chile in Santiago, Chile.

Neurotrope's bryostatin an Orphan Drug for fragile X syndrome
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 7:41AM CDT


Leading Biotech Companies Seek Biologic Treatments for Rare Diseases Utilizing Viable Therapeutic Approach - Company Receives FDA Orphan Drug Designation for Bryostatin
PR Newswire - Thu Apr 09, 7:35AM CDT
According to a recent article published on the Wall Street Journal, the debate over prescription drug pricing has grown increasingly contentious, particularly as drug makers issue more new medicines with high price tags. But despite the tumult, the cost for orphan drugs - medicines that are designated by the FDA to treat a rare disease and may cost as much as $400,000 annually - is apparently not fazing some insurers. Billions of dollars a year are being earmarked for new clinical studies and trials for the treatment of neurodevelopmental disorders as leading biotech companies race to identify treatments for genetic, cognitive, and neural levels for autism disorders. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), Alkermes plc (NASDAQ: ALKS), Regulus Therapeutics Inc. (NASDAQ: RGLS), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Gilead Sciences Inc. (NASDAQ: GILD) and Abbot Laboratories (NYSE: ABT).
ABT: 41.89 (+0.73), INO: 6.16 (+0.20), GILD: 100.65 (-0.16), RGLS: 6.86 (+0.29), ALKS: 60.82 (+0.92)

Neurotrope Receives FDA Orphan Drug Designation for Bryostatin in the Treatment of Fragile X Syndrome
PR Newswire - Thu Apr 09, 7:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope BioScience, Inc., its wholly-owned operating subsidiary, (the "Company" has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its lead proprietary drug candidate, bryostatin, in the treatment of Fragile X Syndrome (FXS).

Research & Clinical Trials for Prevention of Neurodegeneration Search for Viable Therapeutic Approach for the Treatment of Severe Alzheimer's Disease
PR Newswire - Mon Apr 06, 7:35AM CDT
The latest medical research and trials aimed to identify prevention of illnesses, particularly ones related to aging and lifestyle, including Alzheimer's disease, cancer, heart disease and other serious illnesses use innovative and novel approaches to ultimately develop the licensed technology for many types of cognitive dysfunctions. Biotech Companies in focus today: Neurotrope, Inc. (OTC: NTRP), Capnia, Inc. (NASDAQ: CAPN), Arena Pharmaceuticals, Inc., (NASDAQ: ARNA), Orexigen Therapeutics, Inc., (NASDAQ: OREX) & Inovio Pharmaceuticals, Inc., (NASDAQ: INO).
INO: 6.16 (+0.20), OREX: 2.53 (+0.15), CAPNU: (), ARNA: 2.19 (+0.14), CAPN: 2.46 (+0.04)

Neurotrope Selects Worldwide Clinical Trials to Commence Services for Phase 2B Trial of Bryostatin for the Treatment of Alzheimer's Disease
PR Newswire - Mon Apr 06, 7:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the "Company" has selected Worldwide Clinical Trials (WCT) to commence the pre-patient enrollment activities for the conduct of a Phase 2b trial of the Company's compound bryostatin-1 for the treatment of Alzheimer's disease. WCT is a leading global clinical research organization with substantial experience in conducting trials in Alzheimer's disease.

Advances in Biotech Expanded Studies Lead to Cutting-Edge Therapeutic Treatments - Company Announces Positive Final Results in Treatment for Alzheimer's Disease
PR Newswire - Tue Mar 17, 7:35AM CDT
The latest medical projects aimed to prevent illnesses, particularly ones related to aging and lifestyle, including Alzheimer's disease, cancer, heart disease and other serious illnesses use innovative and novel approaches to ultimately develop the licensed technology for many types of cognitive dysfunctions. Biotech Companies in focus today: Neurotrope, Inc. (OTC: NTRP), TG Therapeutics, Inc. (NASDAQ: TGTX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) and Actavis plc (NYSE: ACT)
INO: 6.16 (+0.20), ACT: 298.98 (-2.94), LXRX: 11.59 (-0.05), TGTX: 13.01 (+0.41)

Neurotrope Announces Positive Final Results From its Phase 2a Safety Study for the Treatment of Alzheimer's Disease
PR Newswire - Tue Mar 17, 6:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced secondary and exploratory endpoint results from its randomized, double-blind, placebo-controlled, single dose Phase 2a clinical trial evaluating bryostatin-1 for the treatment of Alzheimer's disease (AD). Bryostatin is a potent modulator of an enzyme called protein kinase C epsilon (PKCe). The Company is approaching the treatment of Alzheimer's disease through the activation of PKCe. In animal models of Alzheimer's disease, activation of PKCe has been shown to improve learning and memory, induce synaptogenesis or growth of new synapses and prevent neurodegeneration.

Neurotrope Forms Clinical Advisory Board to Support Alzheimer's Disease Program
PR Newswire - Wed Jan 14, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced the formation of its Alzheimer's Disease Clinical Advisory Board (CAB) with the following appointments: Jeffery L. Cummings, MD, ScD, CCF, Martin R. Farlow, MD, Sam Gandy, MD, PhD, Christina Sampaio, MD, PhD, and Michael Weiner, MD, among others.

Neurotrope to Present at the Biotech Showcase 2015 Conference
PR Newswire - Wed Jan 07, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced it is scheduled to present at the Biotech Showcase 2015 Conference being held at the Parc 55 Wyndham Hotel in San Francisco, California from January 12 - 14, 2015.

IPOs and Transactions Week in Review: December 1 - 5
PR Newswire - Tue Dec 09, 9:30AM CST
Vintage, the capital markets division of PR Newswire, has released its weekly IPO and Transaction summary.
PGLC: 4.30 (-0.10), IPWR: 7.49 (+0.11)

Neurotrope Announces Last Patient Dosed in Phase 2a Clinical Trial of Bryostatin-1 for Alzheimer's Disease
PR Newswire - Thu Nov 20, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) announced today that the last patient has been dosed in its Phase 2a clinical trial of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD). The trial is being conducted under an Investigational New Drug (IND) application filed by the Company's licensor, the Blanchette Rockefeller Neuroscience Institute (BRNI).

Neurotrope Appoints Warren W. Wasiewski, M.D. as Executive Vice President, Development and Chief Medical Officer
PR Newswire - Thu Nov 06, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced that Warren W. Wasiewski, M.D., F.A.A.P. has joined Neurotrope BioScience, Inc., the Company's wholly owned operating subsidiary, as its Executive Vice President, Development and Chief Medical Officer, effective immediately. Dr. Wasiewski replaces Dr. Richard Scheyer, who had served as Chief Medical Officer since January 2014.
ALXN: 161.08 (-3.23)

Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors
PR Newswire - Thu Sep 18, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment of Larry D. Altstiel, M.D., Ph.D. to the Company's Board of Directors, effective September 12, 2014. The appointment of Dr. Altstiel fills a vacancy on the Board of seven members. Dr. Altstiel will also become Chairman of the Nominating and Corporate Governance Committee and a member of the Audit and Compensation Committees of the Board. He is also a member of Neurotrope's Scientific Advisory Board, a position he has held since October 2013.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 18

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 200

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 95

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 29

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 17

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 136

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 177

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 283

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 62

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Kelly Munson Takes Charge as President and CEO of Independence Health Group

Updated Category News Views 574

Kelly Munson Appointed President and CEO Independence Health Group proudly announces that Kelly A. Munson will take the role of President and Chief Executive Officer. Beginning this new chapter, she will bring with her a wealth of experience and insight derived from her tenure with AmeriHealth Caritas, which operates under the Independence Health Group umbrella....

Continue Reading
Seek AI Achieves Dual Patents, Pioneering AI Data Workflows

Updated Category News Views 201

Innovative Patents Transforming AI Data Analytics NEW YORK-- Seek AI, the agentic AI platform designed for the modern data stack, proudly announces the acquisition of two groundbreaking patents. Awarded by the United States Patent and Trademark Office (USPTO), these patents highlight Seek AI's unique approach to human-in-the-loop workflows that utilize LLM-generated...

Continue Reading
InMed Pharmaceuticals Tackles Nasdaq Compliance Challenges

Updated Category News Views 95

InMed Pharmaceuticals Faces Nasdaq Compliance Challenge InMed Pharmaceuticals Inc. (NASDAQ: INM), a biopharmaceutical firm recognized for its innovative drug development, is actively addressing a delisting notice from Nasdaq, which is due to not meeting minimum bid price regulations. The company has formally initiated an appeal to the Nasdaq Listing Qualifications Panel...

Continue Reading
Tetragon Financial Group Investor Call Highlights and Insights

Updated Category News Views 139

Join Tetragon Financial Group for a Special Investor Call Tetragon Financial Group Limited will be hosting an important investor call to provide key updates about the company. Set for Wednesday, March 5, at 15:30 GMT / 10:30 EST, this call is a significant opportunity for investors to gain insights into Tetragon's annual report and overall company performance. What to...

Continue Reading
Exploring the Future of Bleeding Disorders Treatment Market

Updated Category News Views 214

Growing Landscape of the Bleeding Disorders Treatment Market The Bleeding Disorders Treatment Market is on a significant growth trajectory as it adapts to the rising global prevalence of conditions like hemophilia and other rare coagulation disorders. This upward trend is supported by remarkable advancements in treatment options, increasing healthcare funding, and rising...

Continue Reading